Compare Pfizer Inc (PFE) vs Upwork Inc (UPWK) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

UPWK trades at $9.19, up 1.43% today, with a bullish technical signal from moving averages. The company reported $788M revenue in 2025 with strong profitability margins (net income margin 13.81%) and attractive valuation ratios (P/E 11.52, P/S 1.64). Recent news highlights AI integration initiatives and Q2 2026 earnings anticipation, though legal investigations pose sentiment headwinds.

The outlook is cautiously optimistic with a $10.67 analyst price target suggesting 16% upside. Key opportunities include sustained revenue growth and AI-powered marketplace expansion, while risks involve earnings misses, legal overhangs, and competitive pressures in the gig economy space.